Novedades en dermatología pediátrica

1 Brown MM, Chamlin SL, Smidt AC. Quality of life in pediatric dermatology. Dermatol Clin 2013; 31:211–21.
2 Davis SA, Sandoval LF, Gustafson CJ, et al. Treatment of preadolescent acne in the United States: An analysis of nationally representative data. Pediatr Dermatol 2013; Jul: 1–6.
3 Eichenfield LF, Krakowski AC, Piggott C, et al. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. Pediatrics 2013; 131:163–86.
4 Halvorsen JA, Stern RS, Dalgard F, et al. Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: a population-based study. J Invest Dermatol 2011; 131:363–70.
5 Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol 2012; 26: 1045–60.
6 Ring J, Alomar A, Deleuran M, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part II. J Eur Acad Dermatol Venereol 2012; 26:1176–93.
7 Hoare C, Li Wan Po A, et al. Systematic review of treatments for atopic eczema. Health Technol Assess 2000; 4:1–191.
8 NIAID-sponsored expert panel. Boyce JA, Assa’ad A, et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J Allergy Clin Immunolo 2010; 126:S1–58.
9 Tennis P, Gelfand JM, Rothman KJ. Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. Br J Dermatol 2011; 165:465–73.
10 Leaute-Labreze C, Dumas de la Rogue E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358:2649–51.
11 Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics 2013; 131:128–40.
12 Lou Y, Peng WJ, Cao Y, et al. The effectiveness of propranolol in treating infantile hemangiomas: a meta-analysis including 35 studies. Br J Clin Pharmacol 2013; [Epub ahead of print].
13 Drolet BA, Trenor CC, Brandao LR, et al. Consensus-Derived Practice Standards Plan for Complicated Kaposiform Hemangioendothelioma. J Pediatr 2013; 163:285–91.
14 Ferrari A, Bono A, Baldi M, et al. Does melanoma behave differently in younger children than in adults? A retrospective study of 33 cases of childhood melanoma from a single institution. Pediatrics 2005; 115:649–54.
15 Cordoro KM, Gupta D, Frieden IJ, et al. Pediatric melanoma: Results of a large cohort study and proposal for modified ABCD detection criteria for children. J Am Acad Dermatol 2013; 68:913–25.
16 Vourc’h-Jourdain M, Martin L, Barbarot S. Large congenital melanocytic nevi: therapeutic management and melanoma risk: a systematic review. J Am Acad Dermatol 2013; 68:493–8.
17 Krengel S, Scope A, Dusza SW, et al. New recommendations for the categorization of cutaneous features of congenital melanocytic nevi. J Am Acad Dermatol 2013; 68:441–51.
18 Dickey BZ, Holland KE, Drolet BA, et al. Demographic and clinical characteristics of cutaneous lupus erythematosus at a pediatric dermatology referral center. Br J Dermatol 2013; 169:428–33.
19 Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/ Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation 2012; 126:76–82.
20 Torok KS, Arkachaisri T. Methotrexate and corticosteroids in the treatment of localized scleroderma: a standardized prospective longitudinal single-center study. J Rheumatol 2012; 39:286–94.
21 Zulian F, Vallongo C, Patrizi A, et al. A long-term follow-up study of methotrexate in juvenile localized scleroderma (morphea). J Am Acad Dermatol 2012; 67:1151–6.
22 Pouessel G, Deschildre A, Le Bourgeois M, et al. The lung is involved in juvenile dermatomyositis. Pediatr Pulmonol 2013; 48:1016–25.
23 Kozu KT, Silva CA, Bonfa E, et al. Dyslipidemia in juvenile dermatomyositis: the role of disease activity. Clin Exp Rheumatol 2013; 31:638–44.
24 Mercy K, Kwasny M, Cordoro KM, et al. Clinical manifestations of pediatric psoriasis: results of a multicenter study in the United States. Pediatr Dermatol 2013; 30:424–8.
25 Augustin M, Glaeske G, Radtke MA, et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 2010; 162:633–6.
26 Kimball AB, Wu EQ, Guerin A, et al. Risks of developing psychiatric disorders in pediatric patients with psoriasis. J Am Acad Dermatol 2012; 67:651–7.
27 Varni JW, Globe DR, Gandra SR, et al. Health-related quality of life of pediatric patients with moderate to severe plaque psoriasis: comparisons to four common chronic diseases. Eur J Pediatr 2012; 171:485–92.
28 Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoariasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58:826–50.
29 Marqueling Al, Cordoro KM. Systemic treatments for severe pediatric psoriasis: a practical approach. Dermatol Clin 2013; 31:267–88.
30 Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008; 358:241–51.
31 Gupta A, Paquet M. Systemic antifungals to treat onychomycosis in children: a systematic review. Pediatr Dermatol 2013; 30:294–302.
32 Friedlander SF, Chan YC, Chan YH, et al. Onychomycosis does not always require systemic treatment for a cure: a trial using topical therapy. Pediatr Dermatol 2013; 30:316–22.
33 Mathes EF, Oza V, Frieden IJ, et al. Eczema coxsackium and unusual cutaneous findings in an enterovirus outbreak. Pediatrics 2013; 132:e149–157.